Fri, Oct 31, 2014, 2:57 AM EDT - U.S. Markets open in 6 hrs 33 mins

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • lux19insm@rocketmail.com lux19insm Jul 8, 2014 5:49 PM Flag

    fast money

    any biotech stock that does not have a partner is a take out target........mmmmmmmmmm - what would insm fetch with iPlex and Arikayce?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • IPLEX is worth BILLIONS. It is approved by the FDA for short stature and will be available to sell [drug] in 2018 without any royalty or reparations. Those are the facts. Merck has the connection to manufacture [purchased Colorado facility] and also have used in combination therapy which MDA called breakthrough.

    • lux19insm@rocketmail.com lux19insm Jul 9, 2014 8:10 AM Flag

      Ok let's forget about Terry for a moment and actually talk about the topic...what's the chances of insm fetching a buyout instead of partnering - who would it be - and what price? Seems companies getting a bid for their company who are turning them down have some kind of connection with iPlex. Like Shire and AstraZeneca

      • 1 Reply to lux19insm
      • Maybe Novartis (which would ditch Tobi eventually) then they would own that NTM market for quite awhile. Pure speculation but the changes in early April had an interesting twist with Drayton Wise being added:

        Drayton Wise has joined as Senior Director of Commercial Operations reporting to Matthew Pauls, Chief Commercial Officer. He will focus on the design and build-out of key parts of the Company's commercial infrastructure. Previously, Mr. Wise worked at Novartis, where he led the U.S. sales launch of the TOBI Podhaler, Novartis' leading product for the treatment of CF.

        Sentiment: Buy

    • That statements made on this board about IPLEX are not true.

      IPLEX, as Dr Allen told us who bought this stock for the drug failed to live up to the promise of a being effective in many indications and the company did a lot of trials.

      Dr Allen spoke of the high costs the company would have to pony up and the long timelines.
      I bought this company because of IPLEX and I think those here spreading disinformation about IPLEX are as bad as those bashing before we know about Arikayce or clearly have not done their DD.

      Insmed could very easily have invested the money from their biosimilar plant to produce and trial for ROP.
      They sold it too cheap for eleven million but there is no way Insmed is going to do anything with IPLEX in the future.It would take 18 months just to get a plant up and running before trials that would be 3x as long to finance.

      Name calling from a few(one person) belies the facts of IPLEX future.

 
INSM
14.50-0.09(-0.62%)Oct 30 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.